Acute GVHD (aGVHD) is an immunologic complication of allogeneic hematopoietic cell transplantation (HCT) that can range from mild to life-threatening. Models to predict patients at risk of poor outcomes have been developed using both clinical and laboratory data, and the time to test these models in clinical trials has arrived. However, each modeling method has its potential advantages and limitations. In this mini-review, we summarize recent refinements to these models. We also suggest avenues for improving risk stratification through further studies of a patient's healing capacity and predisposition to endothelial damage, two factors that impact aGVHD outcomes but are absent from the current risk stratification models. 
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Advances in our understanding of the pathophysiology of aGVHD have been made in the years that followed (reviewed in detail elsewhere 3, 4 ). In contrast, despite intense efforts, there has been a lack of major advances in effective aGVHD therapies, perhaps in part because all patients were treated in the same manner, regardless of risk factors.
Acute GVHD can be conceptualized in three phases based upon our understanding of the pathophysiology as derived from animal models and clinical experience: the initiation phase, the lymphocyte trafficking, expansion and effector phase, and the treatment phase (recently reviewed by Holtan et al.) . 3 In the initiation phase of aGVHD, Ag-presenting cells (especially non-hematopoietic host cells 5 ) become activated, present host Ags to donor T lymphocytes and secrete inflammatory cytokines. This series of events culminates in recruitment, activation and proliferation of donor T lymphocytes in the trafficking, expansion and effector phase of aGVHD. As a consequence of this second phase, host tissues (principally skin, intestine, liver and endothelium 6 ) are damaged by infiltrating donor immune effector cells. This vicious aGVHD cycle is perpetuated until effective treatment is initiated.
Despite an increased understanding of the pathophysiology of aGVHD and attempts at novel therapeutic interventions, corticosteroids remain the primary standard therapy for active aGVHD. Approximately 50% of patients experience complete resolution of symptoms related to target end-organ damage. 7 The remaining patients may develop progressive, steroid-refractory aGVHD, a fatal complication for most patients who develop it, 8 or they may continue to have smoldering immune activation possibly leading to chronic GVHD. 9 One of the major challenges that remains daunting in the clinical management of allogeneic hematopoietic cell transplant (HCT) recipients is knowing-in real time-which patients are likely to have mild aGVHD requiring minimal intervention versus those patients with impending fulminant aGVHD requiring more aggressive upfront therapy. Clinical presentation is highly variable in terms of extent and degree of organ involvement, and severity at the onset does not always equate to maximal severity. Furthermore, responses to therapy are often unpredictable.
These clinical challenges highlight the need to identify each patient's trajectory in the course of aGVHD as early as possible, so that any intervention-for example, intensifying therapy to increase response for patients with high-risk (HR) disease or reducing therapy to minimize side effects for patients with lowrisk disease-has the best possible chance of success. Different approaches to risk stratification for patients with aGVHD have recently been developed and refined. These strategies include models built upon initial clinical staging of aGVHD target organs (for example, skin, intestinal tract and liver) and blood biomarker-based approaches. Both of these strategies hold value in identifying HR patients, but neither take into account the endothelium, a key target of aGVHD associated with a poor prognosis. 6, [10] [11] [12] In addition, both of these strategies are based upon the extent of inflammation and tissue damage at presentation. Neither strategy considers the patient's capacity to heal damaged tissues, which recent data indicate may be a critical factor for response to therapy and potentially may explain discrepancies between assigned aGVHD risk and outcome.
In this mini-review, we summarize recent updates in risk stratification models for aGVHD. We define HR aGVHD as patients with a low likelihood of achieving a response (CR or PR) by day 28 after initial conventional steroid therapy, as this end point has been shown to be strongly associated with transplant-related mortality. 13 Although the time has come to begin moving risk-adapted therapy of aGVHD into clinical trials, much work remains to identify the optimal treatment (for example, different doses of systemic steroids or addition of other novel agents) for all patients.
CLINICAL (PATIENT AND DONOR) FACTORS
Several patient-specific factors are associated with clinical outcomes after aGVHD. Patient age, disease risk and conditioning intensity have not been associated with response in multivariate analyses, 14, 15 although patient age is associated with mortality after aGVHD. 7, 15 Pre-transplant comorbidity has recently been shown to be a critical factor in outcomes after aGVHD. A stepwise increase in the risk of severe aGVHD has been observed with increasing hematopoietic cell transplant comorbidity index (HCT-CI), where the probability of grade III-IV aGVHD was 13% in patients with a HCT-CI of 0, 18% with an HCT-CI of 1-4 and 24% with an HCT-CI ⩾ 5. 16 Furthermore, the HCT-CI is significantly associated with mortality after aGVHD, 16 making this pre-transplant assessment a potential objective variable for risk stratification.
Although not as readily identifiable as HCT-CI, recent efforts have been made to identify novel patient-specific factors regarding the capacity to heal after injury, tolerate endothelial stress or changes in the microbiome which may be associated with aGVHD outcomes. Healing of tissue damaged by aGVHD requires angiogenesis and re-epithelialization. Patients with a compromised ability to heal based upon genetic polymorphisms (for example, low production of vascular endothelial growth factor 17 ) may experience increased non-relapse mortality after aGVHD as a consequence. Day 28 CR to first-line aGVHD is associated with increasing levels of vascular endothelial growth factor, possibly indicating improved angiogenesis and wound healing capacity compared with those without a CR. 18 In steroidrefractory aGVHD, levels of thrombomodulin, a protein expressed constitutively on endothelial cells, increase in the serum but decrease in intestinal endothelial cells, 19, 20 suggesting that endothelial vulnerability is an additional key risk factor for outcomes in aGVHD. In 2014, Rachakonda et al. discovered that single-nucleotide polymorphisms within the thrombomodulin gene independently predicted non-relapse mortality after aGVHD in both test and validation sets, lending further evidence to support that a patient's genetically determined endothelial vulnerability can be used for risk stratification after the diagnosis of aGVHD. 21 Finally, recent evidence suggests that preservation of a diverse intestinal microbiome, especially with abundant Blautia species, is associated with reduced aGVHD mortality. 22 Although compelling, assessments of a patient's healing capacity, ability to tolerate endothelial stress or alterations in the intestinal microbiota have not yet made it to the clinic for routine determination of risk but warrant further investigation.
Donor factors also impact outcomes after aGVHD. Female donors have been associated with worse outcomes, both in terms of a higher risk of aGVHD, as well as decreased rates of CR. 1, 23 HLA-mismatched adult unrelated donor graft source is associated with lower CR/PR rates. 7, 14 Interestingly, HLA-mismatched donor status does not appear to be associated with response or survival in the setting of umbilical cord blood transplantation, where the vast majority of grafts are HLA mismatched. In fact, umbilical cord blood graft recipients have equivalent rates of CR/PR and mortality after aGVHD as HLA-matched sibling donor graft recipients, with significantly better CR/PR and mortality rates than unrelated donor recipients. 15 
ORGAN SEVERITY
Initial grade at onset of aGVHD is not consistently associated with response, 1 although maximum overall grade and different patterns of organ severity are associated with outcomes. In 1990, Weisdorf et al. identified in multivariate analyses that overall stage score (sum of each aGVHD organ stage 0-4, plus 1 point for upper gastrointestinal, for a maximum score of 13) was strongly associated with likelihood of CR. 1 In this historical study, single organ involvement was more likely to achieve a CR than multiorgan involvement. Based upon this observation and an ongoing need to better risk stratify patients, the GVHD Risk Score was later developed by the Minnesota group using data from 864 aGVHD consecutive patients from 1990 to 2007. 24 This GVHD Risk Score has recently been refined using data from multiple centers as well as Blood and Marrow Transplant Clinical Trials Network clinical trials 0302 and 0802 15 
), with a day 28 CR/PR rate of 68%. All others are considered HR, with a day 28 CR/PR rate of 44% and only half (52%) of patients surviving beyond 6 months. Because this model can be used in real time at the bedside, it is practical for stratification in clinical trials. However, because~30% of standard risk patients fail to achieve a day 28 CR/PR and die within 6 months after the onset of aGVHD therapy, there is still significant room for further improvement in risk stratification and aGVHD treatment. Although in its most recent iteration, it was tested and validated using patient data from multiple institutions, this model has yet to be validated in prospective manner.
BLOOD BIOMARKERS
The above refined Minnesota Risk Score represents a real-time assessment of aGVHD risk based upon clinical features. The laboratory equivalent of this approach to aGVHD is biomarker discovery through proteomics. 25 Serum proteomic patterns associated with aGVHD were first published~10 years ago. 26, 27 The University of Michigan group has significantly expanded and refined over multiple iterations the proteomic profiling of patients with aGVHD in recent years. They have developed a three-level risk stratification system, as follows: Ann Arbor (AA) 1 low-risk aGVHD, AA2 intermediate-risk aGVHD and AA3 HR aGVHD. The Ann Arbor grade is based upon serum or plasma levels of TNF receptor-1 (TNFR1), regenerating islet-derived 3-alpha (REG3α) and suppression of tumorigenicity 2 (ST2), and has been validated from independent cohorts of patients with aGVHD from the University of Michigan, the University of Regensberg and from multicenter Blood and Marrow Transplant Clinical Trials Network aGVHD treatment trials 0302 and 0802. 28 In these cohorts, non-relapse mortality could be stratified by AA1 versus AA2 versus AA3, although day 28 CR/PR was not significantly different in patients with mild, Glucksberg grade I-II aGVHD and AA1-2 biomarker grades. CR/PR was also not significantly different between AA2 and AA3 biomarker grades in severe, Glucksberg grade III-IV aGVHD, 28 leaving room for future refinement of the algorithm. As with the Minnesota (MN) clinical Risk Score, proteomics-based risk stratification of aGVHD has yet to be tested prospectively.
The laboratory assays to determine serum or plasma levels of TNFR1, REG3α and ST2 are commercially available, but their interpretation requires the Michigan algorithm to identify the probability of (p) of 6-month non-relapse mortality: log[−log(1−p)] = − 9.169+0.598(log 2 TNFR1) − 0.028(log 2 REG3α)+0.189(log 2 ST2). 28 This Ann Arbor risk stratification system will be applied to an upcoming University of Michigan clinical trial of natalizumab plus steroids for the initial treatment of HR AA3 aGVHD (ClinicalTrials. gov identifier NCT02133924). The feasibility of applying this grading system will be tested further in future prospective multicenter clinical trials.
Although less extensively studied, other biomarkers such as serum albumin levels and absolute lymphocyte counts could also serve as potential less expensive, more readily obtainable biomarkers. [29] [30] [31] The challenge of incorporating complex versus simpler blood biomarkers into risk-stratified clinical trial designs is facing the transplant community now. Although the Ann Arbor biomarkers are novel, consideration should still be given to further study of these available clinical laboratory measurements in risk stratification of aGVHD because of their low cost and universal availability. Furthermore, a combination of clinical and laboratory features have not been evaluated in risk stratification of patients with aGVHD. Combining such variables into a composite risk score may provide even more powerful risk stratification than either clinical or laboratory variables alone.
FUTURE CONSIDERATIONS
Even with the advances in risk stratification of aGVHD based upon clinical and laboratory parameters, outcomes are not completely predictable and neither model is ideal. Furthermore, the interventions to be tested based upon risk stratification may be of varying risks themselves. For example, a potentially aggressive intervention in patients assigned to a HR stratum should be performed in such a way as to minimize exposure to patients who are unlikely to benefit from the therapy (that is, the HR stratum has a high positive predictive value for lack of response, with an associated HR of non-relapse mortality). Alternatively, low-risk interventions could potentially be applied to all patients without risk stratification. These issues are key considerations in aGVHD clinical trial development.
It is important to be able to measure the predictive value of a given risk stratification to determine its utility. The Net Reclassification Index (NRI) is a useful tool to measure the ability to predict response and is defined as the net proportion of events assigned to a higher risk category plus the net proportion of nonevents assigned to a lower-risk category. 32 As an example, as measured by the NRI, the refined MN Risk Score was recently shown to improve both the true-positive and false-positive rates among 1723 patients with newly diagnosed aGVHD ( Table 1) . 14 The net percentage of patients more appropriately reclassified both in the positive and negative direction (for example, response versus no response, or survival versus death) is 5% (P o 0.001) for response and 4% for 6-month survival (P o0.001) compared with the original MN definition of GVHD risk. Importantly, the NRI showed that the recently refined MN Risk Score is a better discriminant of outcome for all end points than the original GVHD risk score, 24 Factors that may play important roles in aGVHD risk stratification but are incompletely understood at present include the host healing capacity as genetically predetermined, for example, by single-nucleotide polymorphisms in the genes encoding vascular endothelial growth factor 17 and possibly others. Low-risk aGVHD may one day be defined by a priori knowledge of a patient's comorbidities and healing capacity determined by clinical testing. On the other hand, patients with susceptibility toward endothelial damage, such as those with HR thrombomobulin singlenucleotide polymorphisms 21 or elevated pre-HCT angiopoetin-2 levels, 19 may be classified as HR aGVHD. Currently, host healing capacity and endothelial damage-associated factors are absent from both aGVHD staging and prognostic modeling. With further study, it may become possible to include these important host factors in risk stratification models of aGVHD. In fact, combining these patient-specific biological variables with the HCT-CI may provide further clarity regarding a patient's risk of death due to aGVHD complications before a transplant is even performed.
The best future model to predict aGVHD risk will likely be a combination of clinical and laboratory tests, combining both important patient-specific factors as well as factors that become available (clinical risk algorithms, blood-based biomarkers, assessment of the intestinal microbome) at the time of aGVHD diagnosis. However, such an endeavor to combine these factors has never been undertaken. Although challenging, such a study may be extremely informative for a comprehensive approach to risk stratification of aGVHD.
CONCLUSIONS
With recently refined clinical and laboratory-based methods of aGVHD risk stratification, the time to incorporate these concepts into clinical trial design has arrived. Nonetheless, these models may require ongoing refinement with future patients. Host factors involved in repair of damaged tissues and susceptibility toward endothelial damage also require further study and may further improve upon existing models. In addition, simple, readily available clinical and laboratory data should not be discarded but instead studied further for its utility in prognostication and prediction of outcomes in aGVHD. Finally, although risk stratification is feasible by multiple means, the most appropriate aGVHD therapy for any given risk group remains to be determined. Have we arrived to the place of being able to reliably stratify patients with aGVHD at diagnosis such that their treatment can be risk-adapted accordingly? Outside of clinical trials, we are not there yet. Given recent advancements in both clinical and biomarker-based modeling of aGVHD risk, the era of testing risk stratification in clinical trials for aGVHD treatment has arrived, but the problem of identifying the best immunosuppressive and adjunctive therapies for aGVHD is far from solved. Abbreviations: CIBMTR = Center for International Blood and Marrow Transplant Research; NRI = net reclassification index. The P-value is comparing against the null hypothesis that there is no net benefit to reclassification.
